Literature DB >> 21676918

Early versus later onset childhood-onset systemic lupus erythematosus: Clinical features, treatment and outcome.

J S Hui-Yuen1, L F Imundo, C Avitabile, P J Kahn, A H Eichenfield, D M Levy.   

Abstract

The objective of the study was to compare clinical features, treatment and disease outcome in patients with early versus later onset of childhood-onset systemic lupus erythematosus (cSLE). A retrospective matched cohort study of cSLE patients diagnosed between 1988 and 2008 and followed for a minimum of one year was conducted. Thirty-four pre-pubertal cSLE patients with disease onset prior to their 12th birthday were matched by ethnicity and year of diagnosis to 34 pubertal cSLE patients. The most common criteria at diagnosis in both groups were malar rash, arthritis, hematologic manifestations, and renal disease. After a mean follow-up of more than six years, a similar proportion of patients in the two groups were still prescribed corticosteroids (47% and 41%); patients in the early onset group required a significantly higher daily dose (0.6 mg/kg prednisone-equivalent versus 0.2 mg/kg, p < 0.05). There were no significant differences in organ involvement, disease activity and disease damage between the two groups, and severe complications occurred at similar rates. There were a greater number of admissions to the pediatric intensive care unit (PICU) in the early onset group (18 versus 5, p = 0.01), with time-to-event analysis demonstrating a significantly shorter disease duration from diagnosis to first PICU admission in the early onset group (p < 0.001). While a similar proportion of patients in the early and later onset groups required treatment with cyclophosphamide, patients in the early onset group received treatment earlier in their disease course (mean 13.7 versus 19.9 months, p < 0.001). Early onset cSLE leads to earlier and more frequent PICU admission, earlier use of cyclophosphamide, and higher corticosteroid dose at long-term follow-up.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21676918     DOI: 10.1177/0961203311403022

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  10 in total

1.  Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study.

Authors:  Artemis Koutsonikoli; Maria Trachana; Anna-Bettina Heidich; Vasiliki Galanopoulou; Polyxeni Pratsidou-Gertsi; Alexandros Garyphallos
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

2.  Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.

Authors:  Joyce S Hui-Yuen; Arthi Reddy; Jennifer Taylor; Xiaoqing Li; Andrew H Eichenfield; Liza M Bermudez; Amy J Starr; Lisa F Imundo; Jill Buyon; Richard A Furie; Diane L Kamen; Susan Manzi; Michelle Petri; Rosalind Ramsey-Goldman; Ronald F van Vollenhoven; Daniel J Wallace; Anca Askanase
Journal:  J Rheumatol       Date:  2015-11-01       Impact factor: 4.666

Review 3.  Update on differences between childhood-onset and adult-onset systemic lupus erythematosus.

Authors:  Rina Mina; Hermine I Brunner
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

Review 4.  Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.

Authors:  Marla Guzman; Joyce S Hui-Yuen
Journal:  Drug Des Devel Ther       Date:  2020-06-25       Impact factor: 4.162

5.  Unique Characteristics of Prepubertal Onset Systemic Lupus Erythematosus.

Authors:  R Abdwani; E Abdalla; I Al-Zakwani
Journal:  Int J Pediatr       Date:  2019-05-27

6.  Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK.

Authors:  Joseph S Massias; Eve Md Smith; Eslam Al-Abadi; Kate Armon; Kathryn Bailey; Coziana Ciurtin; Joyce Davidson; Janet Gardner-Medwin; Kirsty Haslam; Dan P Hawley; Alice Leahy; Valentina Leone; Flora McErlane; Devesh Mewar; Gita Modgil; Robert Moots; Clarissa Pilkington; Athimalaipet V Ramanan; Satyapal Rangaraj; Phil Riley; Arani Sridhar; Nick Wilkinson; Michael W Beresford; Christian M Hedrich
Journal:  Lupus       Date:  2021-01-07       Impact factor: 2.911

7.  A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases.

Authors:  Nina M de Gruijter; Meena Naja; Hannah Peckham; Anna Radziszewska; Matthew Kinsella; James Glenister; Elizabeth C Rosser; Gary E Butler; Elizabeth C Jury; Coziana Ciurtin
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-29       Impact factor: 3.054

8.  Increased risk of early-onset childhood systemic lupus erythematosus for children born to affected parents: A nationwide child-parent cohort study.

Authors:  Chun-Hsin Wu; Chih-An Chen; Sheng-Hsiang Lin; Chia-Tse Weng; Pao-Lin Kuo; Chi-Chang Shieh
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

9.  Morbidity and Mortality in Iranian Children with Juvenile Systemic Lupus erythematosus.

Authors:  Fariba Tavangar-Rad; Vahid Ziaee; Mohammad-Hassan Moradinejad; Fatemeh Tahghighi
Journal:  Iran J Pediatr       Date:  2014-07-01       Impact factor: 0.364

10.  Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups.

Authors:  J S Massias; E M D Smith; E Al-Abadi; K Armon; K Bailey; C Ciurtin; J Davidson; J Gardner-Medwin; K Haslam; D P Hawley; A Leahy; V Leone; F McErlane; D Mewar; G Modgil; R Moots; C Pilkington; A V Ramanan; S Rangaraj; P Riley; A Sridhar; N Wilkinson; M W Beresford; C M Hedrich
Journal:  Lupus       Date:  2020-03-31       Impact factor: 2.911

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.